Megan K Schuckman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 825 Centennial Dr, Chadron, NE 69337 Phone: 308-432-4441 Fax: 308-432-2130 |
Emily M Arterburn, APRN Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 825 Centennial Dr, Chadron, NE 69337 Phone: 308-432-4441 Fax: 308-432-2130 |
Edward A Pelton, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 825 Centennial Dr, Chadron, NE 69337 Phone: 308-432-4441 Fax: 308-432-2130 |
Kristin K Johnson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 825 Centennial Dr, Chadron, NE 69337 Phone: 308-432-4441 Fax: 308-432-2130 |
David D Johnson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 825 Centennial Dr, Chadron, NE 69337 Phone: 308-432-4441 Fax: 308-432-2130 |
Jerry L Mclain, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 825 Centennial Dr, Chadron, NE 69337 Phone: 308-432-4441 Fax: 308-432-4446 |
Catherine A Sutera, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 825 Centennial Dr, Chadron, NE 69337 Phone: 308-432-4441 Fax: 308-432-4446 |
Aimy Irenaeia Mahony, APRN-FNP-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 825 Centennial Dr, Chadron, NE 69337 Phone: 308-432-5586 |
News Archive
The report concluded that these weaknesses in the American health system are having a "profound effect" on the overall health of the nation's population.
The U.S. Food and Drug Administration today announced that an orthopedic device used in the knee should not have been cleared for marketing in the United States. The announcement follows a re-evaluation of the scientific evidence that was undertaken after a September 2009 agency report identified problems in the agency's review of the device.
Researchers have demonstrated a new imaging tool for tracking structures called carbon nanotubes in living cells and the bloodstream, which could aid efforts to perfect their use in biomedical research and clinical medicine.
Mylan Inc. today announced that the company's Mylan Pharmaceuticals and Matrix Laboratories subsidiaries entered into a settlement and license agreement with Pfizer Inc. relating to Voriconazole Tablets, 50 mg and 200 mg, the generic version of Pfizer's Vfend Tablets, a triazole antifungal agent.
› Verified 4 days ago